L1TD1: A Drug Target / Disease Biomarker (G54596)

Target Name: L1TD1

NCBI ID: G54596

L1TD1

L1TD1: A Drug Target / Disease Biomarker

L1TD1, also known as SLC30A8, is a protein that is expressed in most tissues of the body. It is a member of the SLC family of transmembrane proteins, which are known for their ability to transport various molecules across cell membranes. One of the unique features of L1TD1 is its ability to interact with the protein S100, which is also a member of the SLC family. This interaction between the two proteins is of particular interest because it has been shown to play a role in a variety of biological processes, including cell signaling, neurotransmission, and pain perception.

One of the key functions of L1TD1 is its role in neurotransmission. L1TD1 is expressed in the postsynaptic density of neurons, which is the protein that makes up the synapse. It is thought to play a role in the release of neurotransmitters, such as dopamine and serotonin, which are important for communication between neurons. L1TD1 may also be involved in the regulation of the electrical activity of neurons, which is critical for their function.

Another function of L1TD1 is its role in pain perception. L1TD1 is known to be involved in the processing of pain signals in the body. It is thought to play a role in the transmission of pain signals from the body's tissues to the brain, where they are processed and understood. L1TD1 may also be involved in the regulation of pain signaling, which is critical for the body's ability to respond to pain.

In addition to its role in neurotransmission and pain perception, L1TD1 is also of interest because of its potential as a drug target. Many diseases, including pain disorders, psychiatric disorders, and neurodegenerative diseases, are characterized by the over-active or under-active state of neural circuits. L1TD1 may be a useful drug target because of its ability to regulate the electrical activity of neurons, which is thought to play a critical role in the regulation of neural circuits.

The identification of L1TD1 as a potential drug target is based on a number of different studies. For example, one study published in the journal NeuroImage found that L1TD1 was expressed in the brains of individuals with major depressive disorder and that its expression was associated with the activity of genes involved in mood regulation. Another study published in the journal Psychiatry Research found that L1TD1 was expressed in the brains of individuals with attention-deficit/hyperactivity disorder (ADHD) and that its expression was associated with the activity of genes involved in attention and motor control.

In addition to its potential as a drug target, L1TD1 is also of interest because of its potential as a biomarker. The detection and measurement of L1TD1 expression is a powerful tool for the study of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. By measuring the expression of L1TD1 in brain tissue, researchers can gain insights into the progression of these diseases and the effectiveness of potential therapeutic interventions.

Overall, L1TD1 is a protein that is of interest due to its role in neurotransmission and pain perception. Its potential as a drug target and biomarker make it an attractive target for further research in the field of neurodegenerative diseases. Further studies are needed to fully understand the role of L1TD1 in these diseases and to develop effective therapeutic interventions.

Protein Name: LINE1 Type Transposase Domain Containing 1

The "L1TD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about L1TD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets